These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 37927079)

  • 1. Comparison of dolutegravir+Lamivudine and bictegravir/emtricitabine/tenofovir alafenamide in antiretroviral therapy-naïve patients infected with HIV: preliminary results from clinical practice.
    Gan L; Xie X; Fu Y; Yang X; Ma S; Kong L; Song C; Song Y; Ren T; Long H
    Expert Rev Anti Infect Ther; 2023 Nov; ():1-8. PubMed ID: 37927079
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Translated article] Real-world persistence with dolutegravir/lamivudine versus bictegravir/emtricitabine/tenofovir-alafenamide among persons with HIV.
    Martín-Zaragoza L; Sánchez-Rubio-Ferrández J; Onteniente-González A; Gómez-Bermejo M; Rodríguez-Álvarez SJ; Monereo-Alonso A; Molina-García T
    Farm Hosp; 2024; 48(4):T171-T175. PubMed ID: 38806363
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An indirect comparison of 144-week efficacy, safety, and tolerability of dolutegravir plus lamivudine and second-generation integrase inhibitor-based, 3-drug, single-tablet regimens in therapy-naive people with HIV-1.
    Evitt LA; Nanji S; Grove RA; Okoli C; van Wyk J; Snedecor SJ
    AIDS Res Ther; 2023 Mar; 20(1):17. PubMed ID: 36949442
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment persistence of bictegravir/emtricitabine/tenofovir alafenamide and efavirenz + lamivudine + tenofovir disoproxil among HIV-1 patients newly starting treatment in Hunan Province in China.
    Jing C; Wei T; Ning W; Fang Z; Gang X; Xingzhi W; Guoqiang Z; Min W
    BMC Infect Dis; 2023 Jun; 23(1):396. PubMed ID: 37308847
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-world persistence with dolutegravir/lamivudine versus bictegravir/emtricitabina/tenofovir-alafenamide among people with HIV.
    Martín-Zaragoza L; Sánchez-Rubio-Ferrández J; Onteniente-González A; Gómez-Bermejo M; Rodríguez-Álvarez SJ; Monereo-Alonso A; Molina-García T
    Farm Hosp; 2024; 48(4):171-175. PubMed ID: 38448360
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparing Real-World Healthcare Costs Associated with Single-Tablet Regimens for HIV-1: The 2-Drug Regimen Dolutegravir/Lamivudine vs. Standard 3- or 4-Drug Regimens.
    Priest J; Germain G; Laliberté F; Duh MS; Mahendran M; Fakih I; Oglesby A
    Infect Dis Ther; 2023 Aug; 12(8):2117-2133. PubMed ID: 37552426
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the design and methodology of Phase 3 clinical trials of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) and dolutegravir-based dual therapy (DTG) in HIV: a systematic review of the literature.
    Grau S; Miró JM; Olalla J; Alcalá JC; Castro A; Rubio-Rodríguez D; Rubio-Terrés C
    Expert Rev Anti Infect Ther; 2023 Jan; 21(1):65-76. PubMed ID: 36399521
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Switching to bictegravir/emtricitabine/tenofovir alafenamide maintained HIV-1 RNA suppression in participants with archived antiretroviral resistance including M184V/I.
    Andreatta K; Willkom M; Martin R; Chang S; Wei L; Liu H; Liu YP; Graham H; Quirk E; Martin H; White KL
    J Antimicrob Chemother; 2019 Dec; 74(12):3555-3564. PubMed ID: 31430369
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety profiles of dolutegravir plus lamivudine vs . bictegravir/emtricitabine/tenofovir alafenamide in therapy-naïve adults with HIV-1.
    Wei Y; Li J; Xu R; Wen L; Deng Y; He L; Zhong H; Wang Y
    Chin Med J (Engl); 2023 Nov; 136(22):2677-2685. PubMed ID: 37914678
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bictegravir/Emtricitabine/Tenofovir Alafenamide in a Multicentre Cohort: Real-Life Experience From Spain.
    Torralba M; Rodríguez G; González Gasca FJ; Cuadra F; Barberá J; Geijo P; Silva A; García MI; Ostaiza MA; García Pérez AM; Arroyo E; Larrubia JR; Gutiérrez A; Porras ML; Calvo Sánchez H; Peña-Asensio J; Arias JG; Mendoza I
    Ann Pharmacother; 2024 Feb; 58(2):140-147. PubMed ID: 37131300
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Decay of HIV RNA in Seminal Plasma and Rectal Fluid in Treatment-Naive Adults Starting Antiretroviral Therapy With Dolutegravir Plus Lamivudine or Bictegravir/Emtricitabine/Tenofovir Alafenamide.
    Scévola S; Niubó J; Domingo P; Verdejo G; Curran A; Diaz-Brito V; Peñafiel J; Tiraboschi J; Morenilla S; Garcia B; Soriano I; Podzamczer D; Imaz A
    J Infect Dis; 2023 Oct; 228(7):919-925. PubMed ID: 37526315
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparing the efficacy and safety of a first-line regimen with emtricitabine/tenofovir alafenamide fumarate plus either bictegravir or dolutegravir: Results from clinical practice.
    Ciccullo A; Baldin G; Borghi V; Oreni L; Lagi F; Fusco P; Giacomelli A; Torti C; Sterrantino G; Mussini C; Antinori S; Di Giambenedetto S
    Int J Antimicrob Agents; 2024 Jan; 63(1):107040. PubMed ID: 37981074
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical efficacy, safety, and subjective experience based on ePRO in HIV-infected individuals administered Bictegravir/Emtricitabine/Tenofovir Alafenamide in southwest China.
    Kong L; Xie X; Fu Y; Gan L; Yang X; Ma S; Long H
    Immun Inflamm Dis; 2023 Aug; 11(8):e974. PubMed ID: 37647435
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tolerability of bictegravir/tenofovir alafenamide/emtricitabine versus dolutegravir/lamivudine as maintenance therapy in a real-life setting.
    Rocabert A; Borjabad B; Berrocal L; Blanch J; Inciarte A; Chivite I; Gonzalez-Cordon A; Torres B; Ambrosioni J; Martinez-Rebollar M; Laguno M; De La Mora L; Foncillas A; Sempere A; Rodriguez A; Solbes E; Llobet R; Miro JM; Mallolas J; Blanco JL; De Lazzari E; Martinez E
    J Antimicrob Chemother; 2023 Dec; 78(12):2961-2967. PubMed ID: 37875023
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Body mass index increase and weight gain among people living with HIV-1 initiated on single-tablet darunavir/cobicistat/emtricitabine/tenofovir alafenamide or bictegravir/emtricitabine/tenofovir alafenamide in the United States.
    Emond B; Rossi C; Côté-Sergent A; Bookhart B; Anderson D; Lefebvre P; Lafeuille MH; Donga P
    Curr Med Res Opin; 2022 Feb; 38(2):287-298. PubMed ID: 34812097
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Renal profile of patients treated with elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide fumarate and dolutegravir/abacavir/lamivudine: 120-week results from a real-world cohort.
    Rotea-Salvo S; Martínez-Pradeda A; Fernández-Oliveira C; Giménez-Arufe V; Balboa-Barreiro V; Margusino-Framiñán L; Mena-De-Cea Á; Vázquez-Rodríguez P; Castro-Iglesias Á; López-Calvo S; Martín-Herranz I; Míguez-Rey E; Cid-Silva P
    Eur J Hosp Pharm; 2023 Jul; 30(4):221-226. PubMed ID: 34649965
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of Virological Efficacy of DTG/ABC/3TG and B/F/TAF Regimens and Discontinuation Patterns in Persons Living with Advanced HIV in the Era of Rapid ART: A Retrospective Multicenter Cohort Study.
    Lee CY; Lee CH; Tang HJ; Tsai HC; Yang CH; Lin YP; Wang SF; Lu PL
    Infect Dis Ther; 2023 Mar; 12(3):843-861. PubMed ID: 36520332
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness and safety of bictegravir/emtricitabine/tenofovir alafenamide in HIV late presenters.
    Corona D; Pérez-Valero I; Camacho A; Gutiérrez Liarte Á; Montero-Alonso M; Alemán MR; Ruiz-Seco P; Pérez González A; Riera M; Jarrin I; Rivero-Juárez A; Rivero A
    Int J Antimicrob Agents; 2024 Jan; 63(1):107016. PubMed ID: 37890734
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir Plus Lamivudine for Switch Therapy in Patients with HIV-1 Infection: A Real-World Cohort Study.
    Gan L; Xie X; Fu Y; Yang X; Ma S; Kong L; Song C; Song Y; Ren T; Long H
    Infect Dis Ther; 2023 Nov; 12(11):2581-2593. PubMed ID: 37845566
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dolutegravir/Lamivudine versus Tenofovir Alafenamide/Emtricitabine/Bictegravir as a Switch Strategy in a Real-Life Cohort of Virogically Suppressed People Living with HIV.
    De Socio GV; Tordi S; Altobelli D; Gidari A; Zoffoli A; Francisci D
    J Clin Med; 2023 Dec; 12(24):. PubMed ID: 38137828
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.